Uniquity Bio Reports Positive Phase 2 Results for Solrikitug
Pennsylvania, November 17, 2026 Uniquity Bio, a clinical-stage biopharmaceutical company focused on immunology and inflammatory diseases and backed by...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Pennsylvania, November 17, 2026 Uniquity Bio, a clinical-stage biopharmaceutical company focused on immunology and inflammatory diseases and backed by...
WAYNE, Pennsylvania, United States — October 27, 2026 Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel treatments for...
Thousand Oaks, California, United States, Aug. 27, 2026 Amgen and AstraZeneca have announced positive top-line results from the Phase...
VANCOUVER, British Columbia, August 13, 202 Eupraxia Pharmaceuticals Inc. reported new symptom-response data from the ongoing Phase 1b/2a portion...
